KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Biogen (BIIB) Finished Goods (2018 - 2019)

Historic Finished Goods for Biogen (BIIB) over the last 5 years, with Q2 2019 value amounting to $144.1 million.

Biogen's Finished Goods changed N/A to $144.1 million in Q2 2019 from the same period last year, while for Jun 2019 it was $144.1 million, marking a year-over-year change of. This contributed to the annual value of $133.5 million for FY2018, which is N/A changed from last year.
Latest data reveals that Biogen reported Finished Goods of $144.1 million as of Q2 2019.
Biogen's 5-year Finished Goods high stood at $144.1 million for Q2 2019, and its period low was $133.5 million during Q4 2018.